Показано 0 из 0
Дата |
---|
10:10 |
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
3.66
|
4.16
|
3.90
|
3.90
|
3.90
|
3.90
|
|
|
|
|
3.80
|
4.12
|
3.82
|
3.82
|
4.08
|
3.96
|
|
|
|
|
3.68
|
4.14
|
3.84
|
3.82
|
4.02
|
3.98
|
|
|
|
|
3.64
|
4.04
|
4.00
|
3.90
|
4.12
|
3.90
|
|
|
|
|
3.86
|
4.32
|
4.06
|
4.06
|
4.16
|
4.16
|
|
|
|
|
3.82
|
4.32
|
4.10
|
4.04
|
4.16
|
4.04
|
|
|
|
|
4.00
|
4.38
|
4.12
|
4.12
|
4.16
|
4.16
|
|
|
|
|
4.00
|
4.26
|
3.92
|
3.92
|
4.12
|
4.12
|
|
|
|
|
3.80
|
4.28
|
3.88
|
3.88
|
4.06
|
3.96
|
|
|
|
|
3.76
|
4.22
|
3.84
|
3.84
|
3.98
|
3.90
|
|
|
|
|
Marker Therapeutics, Inc., formerly known as TapImmune, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.